Gibson Oncology is focused on advancing treatments for brain cancer, specifically through the development of therapies for Glioblastoma and various types of Gliomas. The company has received Orphan Drug Designation (ODD) from the FDA, which highlights the potential of their treatments in addressing these challenging conditions. Gibson Oncology is in the process of finalizing discussions with the National Institutes of Health (NIH) to conduct Phase II Clinical Trials for Glioblastoma, building on foundational research conducted by esteemed institutions such as Purdue University and the Robert Preston Tisch Brain Tumor Center at Duke University. The company has also completed multiple Phase I FDA clinical trials in collaboration with the National Cancer Institute, indicating a robust pipeline of research and development.

The collaborative nature of Gibson Oncology's approach underscores its commitment to leveraging cutting-edge scientific research to inform clinical applications. By working closely with leading research institutions and regulatory bodies, the company aims to bring innovative therapies to market that can significantly impact the treatment landscape for brain cancer. As they progress through clinical trials, Gibson Oncology is poised to provide more detailed information about their developments, reflecting their dedication to transparency and partnership in the fight against these aggressive tumors.

United States

Gibson Oncology is developing a novel class of proprietary drug candidates currently in clinical trials for the treatment of difficult-to-treat tumors.  Our product candidates are first-in-class based upon dual activity at C-MYC and Topo-1 which will improve safety and efficacy and offer future approaches for treating several cancers.  There are currently five (5) ongoing clinical studies funded by the National Institutes of Health in patients with solid tumors and lymphomas.   Finally, Gibson has developed proprietary second-generation product candidates expanding modes of delivery and treatment approaches in both pediatric and adult populations.

Gibson Oncology

Company Details